Navigation Links
Elsevier acquires oncology journal portfolio from Cancer Information Group
Date:2/2/2011

New York, 2 February, 2011 - Elsevier (www.elsevier.com), the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group). The journals publish peer-reviewed, disease specific original research and review articles that disseminate cutting-edge data to physicians, medical researchers and health care professionals.

"These journals provide an excellent addition to Elsevier's oncology portfolio and will further enhance the depth and quality of oncology content published by Elsevier," said Glen P. Campbell, Executive Vice President, Global Medical Research, for Elsevier. "We look forward to working with the editorial teams and to leveraging Elsevier's global resources and market-leading online platforms for the continued development and growth of the quality, international profile and visibility of these prestigious journals."

The specific journal titles are: Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer, and Clinical Genitourinary Cancer.

"Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier," said Campbell.


'/>"/>

Contact: Tom Reller
T.Reller@elsevier.com
215-239-3508
Elsevier
Source:Eurekalert

Page: 1

Related medicine news :

1. Elsevier Foundation announces 2010 grants for libraries in developing countries
2. Elsevier launches innovative online radiology board review product
3. Elsevier announces new partnership with CCS to publish the Canadian Journal of Cardiology
4. Elsevier/MC Strategies and AORN launch perioperative nursing skills collection
5. Elseviers BrainNavigator 3.0 reflects the next step in enhancing neurological research
6. Elsevier launches new journal: Developmental Cognitive Neuroscience
7. Elsevier introduces SciVerse, an innovative platform for accelerating science
8. Gold Standard/Elsevier first to launch state, federal controlled substance drug schedules
9. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
10. Elsevier partners with Helinet to strengthen consortiums leadership in health sciences education
11. Elsevier partners with ASRT to provide multimedia educational modules through Mosbys Imaging Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Hackensack, N.J. (PRWEB) , ... April 26, 2017 ... ... fluency, Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine ... program that recognizes the world’s top women business owners. Winners have demonstrated that ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: